[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@doctorvasan Red-pilled Rebel
Red-pilled Rebel posts on X about $nams, amsterdam, strong, factor the most. They currently have XXXXX followers and XX posts still getting attention that total X engagements in the last XX hours.
Engagements: X #
- X Week XXXXX -XX%
- X Month XXXXXX +32%
- X Months XXXXXX +278%
- X Year XXXXXX +80%
Mentions: X #
- X Week XX no change
- X Month XX +91%
- X Months XXX +293%
- X Year XXX +25%
Followers: XXXXX #
- X Week XXXXX +0.80%
- X Month XXXXX +1%
- X Months XXXXX +5.10%
- X Year XXXXX +8.10%
CreatorRank: undefined #
Social Influence
Social category influence travel destinations XXXX%
Social topic influence $nams 5.71%, amsterdam 2.86%, strong 2.86%, factor XXXX%
Top accounts mentioned or mentioned by @peterattiamd @sanctuarybio @bowtiedbiotech @erictopol @sdut @jpreventionalz1 @lesleyabravanel @nutritionmades3 @doctorrahmeh @simonmaechling @deepakmookram @reuters @visionergeo @amari_zayne
Top assets mentioned NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
Top Social Posts
Top posts by engagements in the last XX hours
"the upcoming ESC/ACC/AHA guidelines following VESALIUS-CV trial results which reinforces ultra-low LDL-C targets for CV risk reduction. FDA has already relaxed criteria for PCSK9i approval this Aug. But the bigger reason may well be approval of Obicetrapib (2/6)"
X Link 2025-12-06T22:54Z 1503 followers, XX engagements
"the new CETPI from New Amsterdam Pharma $NAMS Despite the hangover from past class failures Obi is showing remarkably good safety & tolerability profile apart from efficacy. Plus the combo reduces Lp(a) twice as potently as injectable PCSK9i reduces risk of New onset DM 3/6"
X Link 2025-12-06T22:54Z 1503 followers, XXX engagements
"the atherogenic sdLDL by XX% & showing strong AD biomarker reductions in high risk Apo E4 carriers. To sum up its a multi-target wonder drug in a 💊 with minimal side effects. A quote by senior biotech analyst from Piper Chandler Dr. Yasmeen Rahimi MD PhD (who was a (4/6)"
X Link 2025-12-06T22:54Z 1504 followers, XX engagements
"former Yale Physician research scientist/scholar having led the rare diseases biomarker development program at Shire Pharma encapsulates the Ozempic like excitement Obi is likely to generate upon 🚀. It has the hallmarks to evolve from a lipid drug into a multi-mechanistic . 5/6"
X Link 2025-12-06T22:54Z 1504 followers, XX engagements
"@simonmaechling There is still hope left for AD patients in CETPI Obicetrapib by $NAMS. One factor that distinguishes it from rest of the failed pursuits is support from Mendelian Randomization studies not to mention a robust XX% decline in p-tau217. Watch out for Ph2B trial to start soon"
X Link 2025-12-09T19:29Z 1503 followers, XXX engagements